Serological Evidence of an Early Seroconversion to Simian Virus 40 in Healthy Children and Adolescents

Angelo Taronna1, Elisa Mazzoni2, Alfredo Corallini1, Ilaria Bononi2, Silvia Pietrobon2, Giovanni Guerra3, Caterina Palmonari4, Caterina Borgna-Pignatti5, Manola Comar6, Massimo Bovenzi7, Ferruccio Casali4, Roberto Marcì1, Giovanni Rezza10, Giuseppe Barbanti-Brodano1, Mauro Tognon2-5, Fernando Martini2-5

1 Section of Microbiology, University of Ferrara, Ferrara, Italy, 2 Section of Cell Biology and Molecular Genetics, University of Ferrara, Ferrara, Italy, 3 Clinical Laboratory Analysis, Ferrara City Hospital, Ferrara, Italy, 4 Clinical Laboratory Analysis, County Hospital Delta, Lagozano, Italy, 5 Section of Pediatrics, University of Ferrara, Ferrara, Italy, 6 Institute for Maternal and Child Health – Istituto di Ricerca e Cura a Carattere Scientifico “Burlo Garofolo” – Trieste, University of Trieste, Trieste, Italy, 7 Clinical Unit of Occupational Medicine, Department of Medical Sciences, University of Trieste, Trieste, Italy, 8 Clinical Laboratory Analysis, San Marino State Hospital, Borgo Maggiore, Republic of San Marino, 9 Department of Obstetrics and Genecology, University of Ferrara, Ferrara, Italy, 10 Department of Infectious Diseases, Istituto Superiore di Sanità, Rome, Italy

Abstract

At present Simian virus 40 (SV40) infection in humans appears to be transmitted independently from early contaminated vaccines. In order to test the spread of SV40 infection in children, an immunologic assay employing specific SV40 synthetic peptides corresponding to its viral protein (VP) antigens was employed to estimate the seroprevalence of this polyomavirus in Italian infants and adolescents. Serum samples from 328 children and adolescents, up to 17 years, were investigated. Serum antibodies against SV40 VPs were detected by indirect enzyme-linked immunosorbent assays. The seroprevalence of this polyomavirus was calculated after stratifying the subjects by age. Anti-viral capsid protein 1-2-3 SV40 IgG antibodies were detected in 16% of the study participants. The prevalence of antibodies against SV40 VPz tended to increase with age in children, up to 10 year (21%). Then, in the cohort of individuals aged 11–17 years, the prevalence decreased (16%). A higher prevalence rate (23%) of SV40 VP antibodies was detected in the cohorts of 1–3 year and 7–10 year old children, than in children and adolescents of the other age groups. This age corresponds to children starting nursery and primary school, respectively, in Italy. IgM antibodies against SV40 VP mimotopes were detected in 6–8 month old children suggesting that SV40 seroconversion can occur early in life. SV40 VP antibodies are present at low prevalence in Italian children (16%), suggesting that SV40 infection, although acquired early in life, probably through different routes, is not widespread. The low SV40 seroprevalence suggests that SV40 is less transmissible than other common polyomaviruses, such as BKV and JCV. Alternatively, our immunologic data could be due to another, as yet undiscovered, human polyomavirus closely related to SV40.
Antibodies Reacting with SV40 in Young Individuals

Results

SV40 Antibodies Prevalence and Titer in Serum Samples from Healthy Children and Adolescents

In this investigation, additional comparative computer assisted analyses by BLAST program were carried out with the SV40 VP B and C peptides and the corresponding amino acid (aa) sequences of the new human polyomaviruses 10 (HPyV10) and hundreds of different BKV and JCV serotypes. Our results indicate a low homology, similar to those already reported for the BKV and JCV prototypes and other polyomaviruses [3]. Data are reported in Text S1 and Tables S1–S6. See the section at the end of the article.

In the first step of this study, indirect ELISA was employed to test serum samples which had been diluted at 1/20 and had been taken from healthy subjects aged from 0.1–17 y old. The samples were tested for reactivity to SV40 epitopes from VP1, VP1 B peptide. Serum samples which reacted with the SV40 VP1 B mimotope reached, in children aged up to one year, the prevalence of 13% for SV40 antibodies in the IgG class, then increased with age, reaching 25% in the 1–10 ys age range. Following this, it remained stable in adolescents, from 11–17 ys of age, with the same prevalence of 25%. The overall prevalence in children and adolescents from 0.1–17 ys of age was 21% (69/328).

The same assay was then addressed to detect IgG class serum antibodies against SV40 VP2/3 epitopes, which were present in the VP2/3 C peptide. It turned out that serum samples in the cohort of children, aged 0.1–1 y, reacted with the SV40 VP2/3 C peptide with a prevalence of 11%, which is similar to that detected for the VP1 B peptide. Then, it increased with age with an overall prevalence of 25% detected in the cohort of healthy children aged 1–10 ys, while decreasing to 17% in the cohort of children aged 11–17 ys. Overall, in children aged 0.1–17 ys, the prevalence of antibodies against SV0 peptide VP 2/3 C was 18%. Conversely, seronegative samples for the SV40 VP1 B peptide failed to react with SV40 VP2/3 C epitopes. The exceptions were negligible and were represented by a few serum samples which were found to be negative for VP1 B, while testing positive for VP2/3 C peptide, and vice-versa. The difference was not statistically significant (P=0.05) (Table 1; Fig. 1).

In this investigation, serum samples were considered SV40-positive when reacting with both VP1 B and VP2/3 C peptides.

The overall prevalence by combining SV40-positive sera, both for VP1 B and VP2/3 C peptides, was 16% (Table 1; Fig. 1). No positive results were obtained with human peptide used as a control, which had an OD of less than 0.1 (0.088–0.098). This OD value is usually consistent with SV40-negative sera.

Serum samples tested by indirect ELISA diluted at 1/20 were considered SV40-positive when above the 0.17–0.19 OD, according to the spectrophotometric reading. Indeed, this cut-off point represents the value that discriminates SV40-negative (sample with OD below 0.17–0.19) from SV40-positive samples (OD above 0.17–0.19). The positive control, represented by the SV40 hyperimmune serum, had an OD of up to 1.8, while the two JCV and BKV hyperimmune sera, which were employed as negative controls, had an OD of less than 0.1. A prevalence selection corresponding to 11%, 21%, and 16%, within the cohort aged from 0.1–17 ys old, was observed in subjects aged 0.1–1 y, 1.1–10 ys, 11–17 ys, respectively. The different prevalence of SV40 antibodies between the cohorts of individuals aged 0.1–1 year (11%) was statistically significant compared with cohort of 1.1–10 years (21%) (P = 0.0374). Interestingly, the prevalence of serum antibodies against SV40 VPBs increased with age, with a percentage of 23% in the cohort of children aged 1.1–3 y and 7–10 y old, which is the age in which children start nursery and primary schools, respectively, in Italy (Table 1; Fig. 1). Then, the prevalence declines in the cohort of adolescents 11–17 y old (16%) (Table 1; Fig. 1).

Altogether, serum samples tested by indirect ELISA, diluted at 1:20, had a mean value for both B and C peptides of approximately 0.29 OD, with the highest value of 3.3 OD detected in one serum among those from individuals aged 11–17 y old. Highest level of mean OD values were observed in children aged 7–10 y (0.35 OD, CI = 0.28–0.41) and 11–17 y (0.36 OD, CI = 0.28–0.44) vs. children aged <1–4 months (0.15 OD, CI = 0.11–0.19) with **P<0.001. Fig. 2.

The two indirect ELISA tests, with two distinct VP peptides gave overlapping results, thus confirming the presence of antibodies against SV40 VPBs in human sera from infants and adolescents (Table 1, Fig. 1). The reduced prevalence of SV40-positive sera in infants aged <1 mo-1 y old could be ascribed to a natural age-dependent immune system that is going to become mature, while the mother’s antibodies are no longer detectable. Indeed, it is well established that the immune system physiologically matures with age, rendering individuals more responsive to infections. An alternative interpretation of the result, as suggested
by other studies [16,17] is that the low prevalence of SV40 antibodies in sera from younger children could depend on the low spread of SV40 infectivity in humans (Fig. 1). Serologic profiles of serum antibody reactivity to SV40 mimotopes are presented in Fig. 2.

**IgM Class Antibodies Against SV40 in Serum Samples**

The presence of IgM class antibodies was investigated by indirect ELISA in five IgG SV40-positive sera from children aged 2–8 months. This analysis may indicate when SV40 seroconversion occurs. Two samples from subjects aged 2–4 months were IgM negative, while the other three sera from children aged 6–8 months were IgM positive. This result indicates that SV40 seroconversion can occur in subjects aged 6 months (Table 2).

**ELISA with an Automatic Processing System**

Forty serum samples from young donors, processed using an automatic system gave the same results as previously obtained by manually performing ELISA. Indeed, indirect ELISA was transferred and repeated on the automatic processing system with the DSX instrument (Dynex Technologies Inc., VI, USA). Specifically, the DSX™ Automated ELISA System is a computer-controlled microplate processing system that fully automates ELISAs. This instrument automates the sample distribution, incubation, reagent addition, washing, and detection phases of microplate assays. This result obtained by this instrument is of interest since it indicates that our serologic tests can be easily transferred to an automatic processing system in common clinical laboratory analyses without result variability.

**Discussion**

The prevalence of antibodies to SV40 VPs stratified by age, is shown in Table 1. Overall, 16% of the study population had antibodies against SV40 VPs. The highest relative increase in the proportion of children with antibodies against SV40 VPs was observed in the 1–3 ys and 7–10 ys age group (23%), with more than a 100% increase compared with the age group <1 y old (11%). Subsequently, with age this prevalence declined. Indeed, the prevalence appeared to stabilize for children who were more than 10 y old (16%). It seems that serum antibodies against SV40 have low stability over time. This result is in agreement with previous studies [13,16]. Indeed, overtime the prevalence of SV40 antibodies does not remain stable in the different cohorts of children and adolescents, as demonstrated by a decreased prevalence in the cohorts of subjects aged 3.1–6 ys and 11–

![Figure 1. Comparison of SV40 age-specific seroprevalence of antibodies.](https://example.com/image1.png)

| Age       | Number of Sample | Male % | VP B (%) | VP C (%) | VPs (B–C) (%) |
|-----------|------------------|--------|----------|----------|---------------|
| <1 mo-1 y | 114              | 66     | 15 (13)  | 13 (11)  | 13 (11)*      |
| <1 mo-4 mo| 67               | 5 (7)  | 5 (7)    | 5 (7)    |               |
| 4.1 mo-1 y| 47               | 10 (21)| 8 (17)   | 8 (17)   |               |
| 1.1 y-10 ys| 126             | 52     | 32 (25)  | 32 (25)  | 27 (21)       |
| 1.1 y-3 ys| 35               | 10 (29)| 9 (26)   | 8 (23)   |               |
| 3.1 ys-6 ys| 44              | 9 (20) | 9 (20)   | 8 (18)   |               |
| 7 ys-10 ys| 47               | 13 (28)| 14 (30)  | 11 (23)  |               |
| 11 ys-17 ys| 88              | 56     | 22 (25)  | 15 (17)  | 14 (16)       |
| 1 mo-17 ys| total 328        | 59     | 69 (21)  | 60 (18)  | 54 (16)       |

*Human sera were from healthy children and adolescents. Statistical analysis was performed with Chi-square test.

*The different prevalence of SV40 antibodies between the cohort of individuals aged <1 mo-1 year was statistically significant compared to the cohort of subjects aged 1.1–10 years (P = 0.0374).

doi:10.1371/journal.pone.0061182.t001
17 ys. The SV40 seroprevalence determined in this study was lower than that recently reported on other 9 human polyomaviruses [17,33]. The level of SV40 seroprevalence detected in our study suggests that seroconversion can occur at 6 months of age. This finding is consistent with the high proportion of 1- to 3-y old children with high antibody titers, which may be ascribed to a recent infection.

The Italian pattern appears to differ from that determined in studies conducted in Sweden [16] and U.S. [17] that showed a lower prevalence of antibodies against SV40 VP in children. Our results and comparative data are shown in Fig. 1. The difference observed in the results of studies carried out in children from Italy and Sweden, and U.S. may be due to the different ELISA employed. Indeed, in the Swedish and American assays virus like-particles (VLPs) were used as SV40 antigens [16,17] while in our investigation specific SV40 mimotopes were employed [3,32]. The SV40 VLPs used in the Swedish and U.S. studies were made up by assemblage of only the VP1 capsid protein [16,17] while our peptides contain epitopes of both VP1 and VP2/3. The absence of VP2/3 epitopes in VLPs, with consequent lack of recognition of VP2/3 antibodies, may account for the lower percentage of positive sera in those studies [16,17]. A similar low percentage of adults positive for SV40 antibodies was reported in another study where SV40 VLPs were used as antigens [29]. In this investigation, human sera were adsorbed with BKV and JCV VLPs, thus subtracting a substantial amount of antibodies cross-reacting with SV40 VP epitopes [30]. It has also been proposed that a distinct prevalence of SV40 infection occurs in different countries, as SV40 antibodies in children of different ages suggests that distinct routes of transmission may occur [15]. The low prevalence of children exposed to SV40 is in agreement with the low prevalence of SV40-positive individuals among healthy adults, as was shown in previous studies [3,6,16,20,32,33,36]. Immunological data from this study and other investigations suggest that SV40 is also a human virus. Alternatively, it may be that another, as yet undiscovered polyomavirus infect humans. In this case, positive immunologic data could be due to a new virus closely related to SV40.

**Table 2.** Serum antibodies, IgM and IgG class, reacting in indirect ELISA with SV40 VP mimotopes, from five pediatric subjects aged up to 8 months.

| Subjects | Age | IgG | IgG* | IgM | IgM* |
|----------|-----|-----|------|-----|------|
| Code     | month | OD B/OD C | OD B/OD C |
| 1D       | 2 | 0.245; 0.316 | 0.095; 0.096 |
| 64B      | 4 | 0.149; 0.172 | 0.129; 0.119 |
| 9B       | 6* | 0.240; 0.353 | 0.136; 0.189 |
| 20C      | 8* | 0.444; 0.401 | 0.159; 0.153 |
| 63C      | 8* | 0.443; 0.180 | 0.186; 0.150 |

SV40-positive sera were those samples above the cut-off.

*SV40-negative sample.

IgG cut-off value: Peptide B (0.135 OD), Peptide C (0.143 OD).

IgM cut-off value: Peptide B (0.130OD), Peptide C (0.125 OD).

doi:10.1371/journal.pone.0061182.t002

In conclusion, our data show that the SV40 infection has spread among Italian children, although at a low prevalence. The presence of SV40 antibodies in children of different ages suggests that distinct routes of transmission may occur [15]. The low prevalence of children exposed to SV40 is in agreement with the low prevalence of SV40-positive individuals among healthy adults, as shown in previous studies [3,6,16,20,32,33,36]. Immunological data from this study and other investigations suggest that SV40 is also a human virus. Alternatively, it may be that another, as yet undiscovered polyomavirus infect humans. In this case, positive immunologic data could be due to a new virus closely related to SV40.
Materials and Methods

Human Samples

Serum samples from children and adolescents ($n = 328$; male = 194; female = 134) were collected in the 2009–2012 period. Sera were taken from discarded samples in different Institutions in Italy. They were from the Clinical laboratory analysis, Pediatric Section, Obstetrics and Gynecology, University Hospital of Ferrara, Ferrara; University Hospital of Trieste, Trieste; Clinical laboratory analysis, Delta County Hospital, Lagosanto; Clinical laboratory analysis, State Hospital, Republic of San Marino; Dept. Infectious Diseases, Istituto Superiore di Sanità, Rome. Anonymously collected sera were coded with indications of age and gender, only. The project was approved by the County Ethical Committee of Ferrara. Written consent was given by parents of the children and adolescents involved in this study.

SV40 Mimotopes

Computer assisted analyses allowed us to select 2 specific SV40 peptides, from the late viral region by comparing the three capsid proteins, VP 1-2-3 from SV40, with the amino acids of the human BK (BKV) and JC (JCV) polyomaviruses which are highly homologous to SV40, as well as with other, less homologous polyomaviruses [3]. Previous ELISA results indicated that the two SV40 peptides did not cross-react with the BKV and JCV hyperimmune sera that were employed as controls [3,32]. The amino acid sequences of the two peptides, known as VP1 B and VP2/3 C, respectively, are as follows:

**VP1 B:** NH2- NPDEHQKGLSKSLAAEKQFTDDSP-COOH.

**VP2/3 C:** NH2- IQNDIPRLTSQELERTQRYLRD-COOH.

VP1 B and VP2/3 C mimotopes were selected as they react specifically in indirect ELISA with the rabbit hyperimmune serum that had been experimentally immunized with SV40 (positive control serum). BKV and JCV hyperimmune sera did not react with VP1 B or VP2/3 C peptides (negative control sera). The amino acid residues of the two specific SV40 VPs, B and C peptides, show low homology with the BKV and JCV VPs [3].

The human peptide hNPS, a.a. sequence SFRNGVTGKKTSFQRAKS was employed as a negative control peptide [37]. The synthetic peptides were synthesized using standard procedures and were purchased from UFPeptides s.r.l., Ferrara, Italy [3].

Control Immune Sera

Hyperimmune sera against SV40 and BKV were obtained in rabbits that had been inoculated with purified viral stocks as previously reported [3]. The serum against JCV was kindly provided by Dr. Major, NIH, Bethesda (MD), U.S.A. [38]. The immune serum anti-BKV was titered using a hemagglutination inhibition (H.A.I.) test employing human erythrocytes group 0, Rh+ [3]. Anti SV40 serum was titered by neutralization assay [3]. Additional SV40-negative human sera, employed as controls, were taken from our previous investigations [3,32].

Indirect Enzyme-linked Immunosorbent Assay (ELISA)

Indirect ELISA was developed and standardized to detect specific antibodies against SV40 in human sera using VP1 B VP 2/3 C synthetic peptides [3,32]. **Peptide coating.** Plates were coated with 5 μg of the selected peptide for each well and diluted in 100 μl of Coating Buffer (Candor Bioscience, Germany) at 4°C for 16 hours. **Peptide blocking.** Blocking was made with 200 μl/well of the Blocking Solution (Candor Bioscience, Germany) at 37°C for 16 hours.

**Secondary antibody adding.** Different wells were covered with 100 μl of serum sample diluted 1/20 Low Cross-Buffer (Candor Bioscience, Germany) containing: positive-control to SV40, represented by immune rabbit serum containing anti-SV40 antibodies, negative controls to BKV and JCV represented by immune sera anti-BKV and anti-JCV, and three human serum samples which were found to be SV40-negative in our previous investigation [3]. Each sample was analyzed three times in duplicate wells. **Secondary antibody adding.** The solution contained a goat anti-human or anti-rabbit IgG heavy and light chain specific peroxidase-conjugate (Calbiochem-Merck, Germany) or peroxidase-labeled affinity purified antibody to human IgM heavy chain μ peroxidase-conjugate (KPL Gaithersburg MD, USA) diluted 1:10,000 in Low Cross-Buffer [39]. **Dye treatment and spectrophotometric reading.** Samples were treated with 100 μl of 2,2'-azino-bis 3-ethylbenzthiazoline-6-sulfonic acid (ABTS) solution (Sigma-Aldrich, Milan), for 45 min. at RT, and then read on the spectrophotometer (Thermo Electron Corporation, model Multisaker EX, Finland) at a wavelength (λ) of 405 nm. The color intensity in wells where the immunocomplexes were formed was determined by optical density (OD). **Automatic ELISA.** The serologic analysis of human sera, performed by the manual ELISA procedure, was transferred and repeated by an ELISA automatic processing system on the DSX instrument (Dynex Technologies Inc., VI, USA). Cut-off determination. The cut-off point was determined in each assay by the value of an OD reading of three negative controls, that was added to the standard deviation multiplied three times (+3SD). Sera with antibodies against SV40 were considered VP-positive upon reacting to both peptides of the late region and when sera that had been analyzed three times by indirect ELISA testing gave the same positive result. SV40 antibody titer was determined by serial dilutions of sera from 1:20 to 1:640.

Cell, Viruses and Neutralization Assay

Viral working stocks were obtained in Vero cells infected with the SV40 776 strain or BKV Gardner strain, as described previously [3]. Permissive CV-1 monkey kidney cells were used for the neutralization assay of SV40 infectivity, as described [3]. BKV and JCV hemagglutination (H.A.) and H.A.I. titrations were carried out as described in detail elsewhere [3].

Statistical Analysis

Statistical analyses were performed using Prism software (GraphPad, San Diego, CA). Data are presented as a percentage of positive samples. The 95% Confidence Intervals (CI) of the percentage of positive samples are also reported. Differences among proportions were calculated by Chi-square test for independence in the contingency tables.

Supporting Information

Table S1 SV40 VP1, peptide B compared to JCV VP1.

Table S2 SV40 VP 2/3 peptide C, compared to JCV VP2-3.

Table S3 SV40 VP1, peptide B compared to BKV VP1.

Table S4 SV40 VP2/3, peptide C compared to BKV VP2-3.
Table S5  SV40 VP1 peptide B compared to HPyV10 VP1. (DOC)

Table S6  SV40 VP2/3 peptide C compared to HPyV10 VP2-3. (DOC)

Text S1  Comparative homology analyses of amino acid sequences of SV40 VP1 B and VP2/3 C peptides with the corresponding JCV, BKV and HPV10 VPs. (DOC)

References
1. Barbanti-Brodano G, Sabbioni S, Martini F, Negrini M, Corallini A, et al. (2004) Simian virus 40 infection in humans and association with human diseases: results and hypotheses. Virology 318: 1–9.
2. Martini F, Corallini A, Balati V, Sabbioni S, Pancaldi G, et al. (2007) Simian virus 40 in humans. Infect Agent Cancer 2: 13.
3. Corallini A, Mazzoni E, Taronna A, Manfrini M, Carandina G, et al. (2012) Specific antibodies reacting with simian virus 40 capsid protein mimotopes in sera from healthy donors. Hum Immunol 73: 502–510.
4. Martini F, Dolecki R, Gloghini A, Iaccheri L, Carbone A, et al. (1996) Simian virus-40 footprints in human lymphoproliferative disorders of HIV- and HIV+ patients. Int J Cancer 78: 669–674.
5. Dolecki R, Martini F, Quisai M, Gloghini A, Vignocchi B, et al. (2003) Simian virus 40 sequences in human lymphoblastoid B-cell lines. J Virol 77: 1595–1597.
6. Pancaldi C, Balati V, Guaschino R, Vaniglia F, Corallini A, et al. (2009) Simian virus 40 sequences in blood specimens from healthy individuals of Casale Monferrato, an industrial town with a history of asbestos pollution. J Pathol 212: 710–717.
7. Bocchetta M, Di Resta I, Poretti A, Fresco R, Tosolini A, et al. (2000) Human simian virus 40 sequences similar to those of simian virus 40 in ependymomas and choroid plexus tumors. PLoS Pathog 5: e1000363.
8. Barbanti-Brodano G, Corallini A, Acella RS, Martini F, Tognon M (2004) SV40 infections in hospitalized children. Hum Pathol 35: 1496–1502.
9. Morelli C, Barbisa F, Iaccheri L, Tognon M (2004) SV40-immortalized human fibroblasts as a source of SV40 virions. Mol Med 10: 112–116.
10. Mazzoni E, Corallini A, Cristaudo A, Taronna A, Tassi G, et al. (2012) High incidence of SV40-like sequences detection in tumour and peripheral blood specimens. J Virol Dis 192: 658–664.
11. Vanchieri JA, Nacmce KK, Greer JM, Demmger JJ, Butel JS (2005) Frequent detection of polyomavirus in tonsil samples from hospitalised children. J Infect Dis 192: 658–664.
12. Butel JS, Arrington AS, Wong C, Leducyka JJ, Finegold MJ (1999) Molecular evidence of simian virus 40 infections in children. J Infect Dis 180: 884–887.
13. Butel JS, Jafar S, Wong C, Arrington AS, Opekun AR, et al. (1999) Evidence of SV40 infections in hospitalized children. Hum Pathol 30: 1496–1502.
14. Vanchieri JA, White ZS, Butel JS (2005) Detection of BK virus and simian virus 40 in the urine of healthy children. J Med Virol 77: 447–454.
15. Patel NC, Vakilz RA, Killen DE, Zavars F, Sverdl V, et al. (2008) Detection of polyomavirus SV40 in tonsils from immunocompetent children. J Clin Virol 43: 66–72.
16. Lundquist A, Elissiou L, Lethinen M, Saanakan M, Koivula P, et al. (2005) Prevalence and stability of human serum antibodies to simian virus 40 VP1 virus-like particles. J Gen Virol 86: 1705–1708.
17. Kean JM, Rao S, Wang M, Garceo RL (2009) Seroeplidemiology of human polyomaviruses. PLoS Pathog 5: e1000363.
18. Bergsagel D, Finegold MJ, Butel JS, Kuspy WH, Garceo RL (1992) DNA sequences similar to those of simian virus 40 in ependymomas and choroid plexus tumors of childhood. N Engl J Med 326: 908–909.
19. Lednicky JA, Garceo RL, Bergsagel D, Butel JS (1995) Natural simian virus 40 strains are present in human choroid plexus and ependymoma tissues. Virology 212: 710–717.
20. Martini F, Iaccheri L, Lazzarin L, Carinci P, Corallini A, et al. (1996) SV40 early region and large T antigen in human brain tumors, peripheral blood cells, and sperm fluids from healthy individuals. Cancer Res 56: 4820–4825.
21. Carboni M, Rizzio P, Procaccio A, Giuliano M, Pace HI, et al. (1996) SV40-like sequences in human bone tumors. Oncogene 15: 527–535.

Acknowledgments
We would like to thank Dr. Eugene O. Major, the Laboratory of Molecular Medicine and Neuroscience, the National Institute of Neurological Disorders and Stroke, Bethesda, MD, for the hyperimmune serum against JCV.

Author Contributions
Conceived and designed the experiments: AC GBB GR MT FM. Performed the experiments: AT EM AC IB SP FM. Analyzed the data: AT EM AC GG CP CB MC MB FC RM GR. Contributed reagents/materials/analysis tools: GG CP MC CB MB FC RM GR. Wrote the paper: EM AC GR GBB FM MT.